7855 related articles for article (PubMed ID: 33537094)
21. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
Suda K; Rozeboom L; Rivard CJ; Yu H; Ellison K; Melnick MAC; Hinz TK; Chan D; Heasley LE; Politi K; Mitsudomi T; Hirsch FR
Lung Cancer; 2017 Jul; 109():1-8. PubMed ID: 28577937
[TBL] [Abstract][Full Text] [Related]
22. Integrin αVβ1-activated PYK2 promotes the progression of non-small-cell lung cancer via the STAT3-VGF axis.
Wu Z; Jiao M; Shu C; Zhang S; Wang J; Pu J; Zhu J; Zeng Y; Zhu Y; Liu Z
Cell Commun Signal; 2024 Jun; 22(1):313. PubMed ID: 38844957
[TBL] [Abstract][Full Text] [Related]
23. Immunoglobulin-like transcript 4 promotes tumor progression and metastasis and up-regulates VEGF-C expression via ERK signaling pathway in non-small cell lung cancer.
Zhang P; Guo X; Li J; Yu S; Wang L; Jiang G; Yang D; Wei Z; Zhang N; Liu J; Sun Y
Oncotarget; 2015 May; 6(15):13550-63. PubMed ID: 25948790
[TBL] [Abstract][Full Text] [Related]
24. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
[TBL] [Abstract][Full Text] [Related]
25. Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation.
Cao D; Chen D; Xia JN; Wang WY; Zhu GY; Chen LW; Zhang C; Tan B; Li H; Li YW
Biomed Pharmacother; 2022 Nov; 155():113705. PubMed ID: 36271541
[TBL] [Abstract][Full Text] [Related]
26. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.
Jiang XM; Xu YL; Huang MY; Zhang LL; Su MX; Chen X; Lu JJ
Acta Pharmacol Sin; 2017 Nov; 38(11):1512-1520. PubMed ID: 28880013
[TBL] [Abstract][Full Text] [Related]
27. Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.
Shibahara D; Tanaka K; Iwama E; Kubo N; Ota K; Azuma K; Harada T; Fujita J; Nakanishi Y; Okamoto I
J Thorac Oncol; 2018 Jul; 13(7):926-937. PubMed ID: 29596910
[TBL] [Abstract][Full Text] [Related]
28. Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging.
Li D; Zou S; Cheng S; Song S; Wang P; Zhu X
Mol Pharm; 2019 Aug; 16(8):3469-3476. PubMed ID: 31283253
[TBL] [Abstract][Full Text] [Related]
29. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
Xie C; Zhou X; Liang C; Li X; Ge M; Chen Y; Yin J; Zhu J; Zhong C
J Exp Clin Cancer Res; 2021 Aug; 40(1):266. PubMed ID: 34429133
[TBL] [Abstract][Full Text] [Related]
30. Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.
Watanabe S; Hayashi H; Haratani K; Shimizu S; Tanizaki J; Sakai K; Kawakami H; Yonesaka K; Tsurutani J; Togashi Y; Nishio K; Ito A; Nakagawa K
Cancer Sci; 2019 Jan; 110(1):52-60. PubMed ID: 30390416
[TBL] [Abstract][Full Text] [Related]
31. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH
Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282
[TBL] [Abstract][Full Text] [Related]
32. ILT4 drives B7-H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7-H3 co-expression correlates with poor prognosis in non-small cell lung cancer.
Zhang P; Yu S; Li H; Liu C; Li J; Lin W; Gao A; Wang L; Gao W; Sun Y
FEBS Lett; 2015 Aug; 589(17):2248-56. PubMed ID: 26149216
[TBL] [Abstract][Full Text] [Related]
33. Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer.
Zhang H; Dutta P; Liu J; Sabri N; Song Y; Li WX; Li J
J Cell Mol Med; 2019 Jan; 23(1):535-542. PubMed ID: 30378264
[TBL] [Abstract][Full Text] [Related]
34. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
[TBL] [Abstract][Full Text] [Related]
35. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.
Lin A; Wei T; Meng H; Luo P; Zhang J
Mol Cancer; 2019 Sep; 18(1):139. PubMed ID: 31526368
[TBL] [Abstract][Full Text] [Related]
36. Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice.
Jia Y; Zhao S; Jiang T; Li X; Zhao C; Liu Y; Han R; Qiao M; Liu S; Su C; Ren S; Zhou C
Lung Cancer; 2019 Nov; 137():85-93. PubMed ID: 31563735
[TBL] [Abstract][Full Text] [Related]
37. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
Soo RA; Lim SM; Syn NL; Teng R; Soong R; Mok TSK; Cho BC
Lung Cancer; 2018 Jan; 115():12-20. PubMed ID: 29290252
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
39. CD147-mediated glucose metabolic regulation contributes to the predictive role of
Li X; Fu Q; Zhu Y; Wang J; Liu J; Yu X; Xu W
Mol Carcinog; 2019 Feb; 58(2):247-257. PubMed ID: 30320488
[TBL] [Abstract][Full Text] [Related]
40. Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function.
La Fleur L; Botling J; He F; Pelicano C; Zhou C; He C; Palano G; Mezheyeuski A; Micke P; Ravetch JV; Karlsson MCI; Sarhan D
Cancer Res; 2021 Feb; 81(4):956-967. PubMed ID: 33293426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
